Iterum Therapeutics Q4 2023 GAAP EPS $(0.94), Inline, Cash Position $23.9M
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics reported its Q4 2023 earnings with a GAAP EPS of $(0.94), meeting the analyst consensus estimate. The company also reported a cash position of $23.9M.
March 28, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Iterum Therapeutics reported a Q4 2023 GAAP EPS of $(0.94), in line with analyst expectations, and a cash position of $23.9M.
Meeting the analyst consensus estimate generally indicates that the company's financial performance was as expected, which could lead to a neutral short-term impact on the stock price. The reported cash position provides insight into the company's liquidity, which is crucial for its operations and future investments.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100